Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market.
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca’s Asthma Drug On Efficacy, Analysts Say
Where Today's News Shapes Tomorrow
